In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims

1) (Currently Amended) A method for identifying a binding member capable of occupying a substrate binding site on the CCT complex or part thereof, wherein the binding member inhibits the binding of the CCT substrate to ~~and~~ the CCT complex or part thereof.

2) (Previously Amended) A method according to claim 1 wherein the binding member is an antibody.

3) (Currently Amended) A method according to claim 1 wherein the binding member is ~~selected from the group consisting of~~ a peptide ~~and a peptide fragment~~.

4) (Previously Amended) A method according to claim 3 wherein the binding member is greater than 5 amino acids in length.

5) (Previously Amended) A method according to claim 4 wherein the binding member is from 5 to 40 amino acids in length.

6) (Previously Amended) A method according to claim 3 wherein the binding member is derived from a CCT substrate.

7) (Currently Amended) A method according to claim 6 wherein the substrate from which the binding member is derived is selected from the group consisting of actin, tubulin or cyclin.

8) (Currently Amended) A method according to claim 7 wherein the substrate from which the binding member is derived is actin.

9) (Currently Amended) A method according to claim 3 wherein the binding member comprises a sequence selected from the group of SEQ ID NOS: 1-15 ~~sequences shown in Figure 10~~.

10) (Previously Amended) A method according to claim 9 wherein the binding member comprises the amino acid sequence GRPRH (SEQ ID NO: 121).

11) (Currently Amended) A method of identifying a binding member capable of occupying a substrate binding site on a CCT apical domain; comprising the steps of

contacting a candidate binding member with said CCT apical domain; and

determining binding between said candidate binding member and the CCT apical domain

wherein the binding member inhibits the binding of the CCT substrate to the CCT apical domain.

12) (Currently Amended) A method according to claim 11 wherein the binding member is ~~selected from the group consisting of~~ a peptide ~~and a peptide fragment~~.

13) (Currently Amended) A method according to claim 12 wherein the candidate binding member is a peptide ~~or peptide fragment~~ having an amino acid sequence corresponding to the amino acid sequence of a CCT ~~apical domain~~ substrate.

14) (Original) A method according to claim 13 wherein the CCT substrate is actin.

15) (0riginal) A method according to claim 14 wherein the CCT substrate is tubulin.

16) (Currently Amended) A method according to claim 12 wherein the peptide ~~or peptide fragment~~ comprises a sequence selected from the group of sequences shown in ~~Fig. 10~~ SEQ ID NOS 1 – 15.

17) (Previously Amended) A method according to claim 11 further comprising the step of immobilizing the candidate binding member on a solid phase prior to contacting with the CCT apical domain.

18) (Previously Amended) A method according to claim 11 further comprising the step of modifying the candidate binding member to improve its binding with the CCT apical domain.

19) (Previously Amended) A method according to claim 11 wherein binding between the candidate binding member and the CCT apical domain is determined by a competitive assay.

20) (Currently Withdrawn) A binding member capable of occupying a CCT substrate binding site, comprising of an amino acid sequence of 5 to 40 amino acids derived from a CCT substrate.

21) (Currently Withdrawn) A binding member according to claim 20 wherein the CCT substrate is selected from the group consisting of actin, tubulin or cyclin.

22) (Currently Withdrawn) A binding member according to claim 21 wherein the CCT substrate is actin.

23) (Currently Withdrawn) A binding member according to claim 22 comprising any one of the amino acid sequences selected from the group of sequences shown in Fig. 10.

24) (Currently Withdrawn) A binding member according to claim 23 comprising the amino acid sequence GRPRH **(SEQ ID NO: 121).**

25) (Currently Withdrawn) A binding member according to claim 20 having binding affinity for a CCT complex such that it blocks a substrate binding site on said CCT complex thereby effecting the biological activity of the CCT complex.

26) (Currently Withdrawn) A binding member according to claim 20 linked to a coupling partner.

27) (Currently Withdrawn) A binding member according to claim 26 wherein the coupling partner is a second peptide and the binding member and the second peptide form a fusion protein.

28) (Currently Withdrawn) A binding member according to claim 20 for use in medical treatment.

29) (Currently Withdrawn) A medicament for the treatment of cancer cells, said medicament comprising a binding member as claimed in claim 20, said medicament being administered to said cells to effect the biological activity of a CCT complex within the cell.

30) (Currently Withdrawn) A medicament according to claim 29 wherein the medicament further comprises a cancer drug.

31) (Currently Amended) A method for screening for mimetics of binding members capable of occupying a CCT substrate binding site, comprising of an amino acid sequence of 5 to 40 amino acids derived from a CCT substrate, wherein said binding member has been identified by a method of claim 1or claim 11, the method ~~according to claim 20~~ comprising exposing said binding members and a candidate mimetic to a CCT substrate binding site ~~or active portion thereof~~, so that the candidate mimetic and the binding member compete to bind to the CCT substrate binding site; and detecting the extent of binding of the candidate mimetic or the binding member to the CCT substrate binding site; wherein a mimetic of the binding members binds to the CCT substrate binding site or reduces the extent of binding of the binding member o the CCT substrate binding site.

32) (Currently Amended) A method according to claim 31 further comprising screening the candidate mimetics for ~~biological activity~~ the ability to affect the normal biological activity of CCT in a cell.

33) (Original) A method according to claim 32 wherein the biological activity is the inhibition of cytoskeletal assembly.

34) (Original) A method according to claim 32 wherein the biological activity is CCT complex dis-assembly.

35) (Currently Amended) A method according to claim ~~27~~ 31 wherein the binding member or the candidate mimetic is immobilized on a solid support.

36) (Currently Amended) A method according to claim 31 wherein the extent of binding of the candidate mimetic is detected by labelling the CCT substrate binding site complex or part thereof having a substrate binding site ~~active portion thereof~~ or by using a labelled antibody capable of binding to the CCT substrate binding domain.

37) (Previously Amended) A method according to claim 36 wherein the CCT substrate binding site comprises the sequence corresponding to residues D219 to N394 of CCTδ.

38) (Currently Withdrawn) A pharmaceutical composition comprising a binding member according to claim 20 in combination with a pharmaceutically acceptable carrier.

39) (Currently Withdrawn) A CCT apical domain having at least 80% homology with the amino acid sequence of D219 to N394 of CCTδ.

40) (Currently Withdrawn) A nucleic acid molecule encoding the polypeptide according to claim 39.

41) (Currently Withdrawn) A vector comprising the nucleic acid according to claim 40.

42) (Currently Withdrawn) A host cell comprising the vector according to claim 41.

43) (Currently Withdrawn) A host cell comprising the nucleic acid according to claim 40.